[en] BACKGROUND: Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature. AIM: The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD. METHODS: All relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach. RESULTS: Different commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence. CONCLUSION: Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Reenaers, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Bossuyt, Peter; Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Hindryckx, Pieter; Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium.
Vanpoucke, Hilde; Department of Laboratory Medicine, AZ Delta, Roeselare-Menen, West-Vlaanderen, Belgium.
Cremer, Anneline; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Belgium.
Baert, Filip; Department of Gastroenterology, AZ Delta, Roeselare, Belgium.
Language :
English
Title :
Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.
Magro F, Gionchetti P, Eliakim R, Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670
Gomollón F, Dignass A, Annese V, 3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25
Birko S, Dove ES, Özdemir V. Evaluation of nine consensus indices in Delphi foresight research and their dependency on Delphi survey characteristics: A simulation study and debate on Delphi design and interpretation. PLoS One 2015; 10: e0135162–e0135162
Lasson A, Stotzer PO, Öhman L, The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015; 9: 26–32
Røseth AG, Fagerhol MK, Aadland E, Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793–798
Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: Comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2013; 51: 825–831
Elkjaer M, Burisch J, Voxen Hansen V, A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 323–330
De Sloovere MMW, De Smet D, Baert FJ, Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med 2017; 55: 1435–1446
Heida A, Knol M, Kobold AM, Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol 2017; 15: 1742–1749
Amcoff K, Stridsberg M, Lampinen M, Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol 2017; 52: 344–350
Menees SB, Powell C, Kurlander J, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110: 444–454
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010; 341: c3369–c3369
D’Haens G, Ferrante M, Vermeire S, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218–2224
Peyrin-Biroulet L, Sandborn W, Sands BE, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324–1338
Sipponen T, Savilahti E, Kolho KL, Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40–46
Mosli MH, Zou G, Garg SK, C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 802–819; quiz 820
Hoekman DR, Diederen K, Koot BG, Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016; 175: 1335–1342
Schoepfer AM, Beglinger C, Straumann A, Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162–169
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817–1826.e2
Naismith GD, Smith LA, Barry SJ, A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther 2013; 37: 613–621
Mooiweer E, Severs M, Schipper ME, Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: A plea for deep remission. J Crohns Colitis 2015; 9: 50–55
Sipponen T, Björkesten CG, Färkkilä M, Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol 2010; 45: 325–331
Theede K, Kiszka-Kanowitz M, Nielsen AM, The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol 2014; 49: 418–423
De Vos M, Dewit O, D’Haens G, Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 2012; 6: 557–562
Colombel JF, Panaccione R, Bossuyt P, Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390: 2779–2789
Sandborn WJ, Feagan BG, Rutgeerts P, Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721
Molander P, af Björkesten CG, Mustonen H, Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012; 18: 2011–2017
Turner D, Leach ST, Mack D, Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: A prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207–1212
Sipponen T, Kärkkäinen P, Savilahti E, Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221–1229
Mao R, Xiao YL, Gao X, Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–1899
García-Sánchez V, Iglesias-Flores E, González R, Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144–152
Louis E, Mary JY, Vernier-Massouille G, Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70.e5. quiz 70.e31
Molander P, Färkkilä M, Ristimäki A, Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015; 9: 33–40
Cosnes J, Gower-Rousseau C, Seksik P, Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785–1794
Regueiro M, Strong SA, Ferrari L, Postoperative medical management of Crohn’s disease: Prevention and surveillance strategies. J Gastrointest Surg 2016; 20: 1415–1420
Rutgeerts P, Geboes K, Vantrappen G, Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956–963
Yamamoto T, Shiraki M, Bamba T, Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J 2013; 1: 368–374
Wright EK, Kamm MA, De Cruz P, Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology 2015; 148: 938–947.e1
Yamamoto T, Shimoyama T, Umegae S, Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn’s disease: A long-term prospective study. Therap Adv Gastroenterol 2016; 9: 664–670
Yamamoto T, Shimoyama T, Bamba T, Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol 2015; 110: 881–887
